Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Refined elderly comorbidity index is highly predictive of post-transplant survival in older adults with Acute Myeloid Leukemia and myelodysplastic syndrome

Blood (2025) 146 (Supplement 1): 6076.

https://doi.org/10.1182/blood-2025-6076

Published: 2025

Journal Articles

Outcomes of elderly (≥ 70) Acute Myeloid Leukemia (AML) patients receiving continued hypomethylating agent/venetoclax (HMA/VEN) versus allogeneic hematopoietic cell transplantation (HCT)

Blood (2025) 146 (Supplement 1): 4300.

https://doi.org/10.1182/blood-2025-4300

Published: 2025

Journal Articles

Effect of GVHD prophylaxis on renal function and survival outcomes in allogeneic hematopoietic cell transplant patients with pre-existing renal impairment

Blood (2025) 146 (Supplement 1): 7764.

https://doi.org/10.1182/blood-2025-7764

Published: 2025

Journal Articles

Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML)

Onyee Chan, Kendra Sweet, Chetasi Talati, Fatima Tuz Zahra, Lisa Nardelli, Jatinder Lamba, Jongphil Kim, Jinming Song, Samuel Reynolds, Rory Shallis, Zhuoer Xie, Seongseok Yun, Andrew Kuykendall, Eric Padron, Alison Walker, Rami Komrokji, Jeffrey Lancet, David Sallman

Blood (2025) 146 (Supplement 1): 5216.

https://doi.org/10.1182/blood-2025-5216

Published: 2025

Journal Articles

Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL)

Yumeng Zhang, Jongphil Kim, Richard Corona, Shannen Whiddon, Janice Bennett, Anthony Suda, Bijal Shah, Celeste Bello, Julio Chavez, Leidy Isenalumhe, Sameh Gaballa, Javier Pinilla-Ibarz, Frank Glass, Lubomir Sokol

Blood (2025) 146 (Supplement 1): 1881.

https://doi.org/10.1182/blood-2025-1881

Published: 2025

Journal Articles

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Blood (2025) 146 (Supplement 1): 4537.

https://doi.org/10.1182/blood-2025-4537

Published: 2025

Journal Articles

Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy

Blood blood.2025029921.

https://doi.org/10.1182/blood.2025029921

Published: 2025

Includes: Supplemental data

Journal Articles

Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes

Blood (2025) 145 (15): 1645–1657.

https://doi.org/10.1182/blood.2024024965

Published: 2025

Includes: Supplemental data

Journal Articles

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

Blood (2024) 144 (22): 2295–2307.

https://doi.org/10.1182/blood.2024024789

Published: 2024

Includes: Supplemental data

Journal Articles

Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia

Abida Babu, Kathryn Bower, Madiha Siraj, Biwei Cao, Jongphil Kim, Hany Elmariah, Rawan Faramand, Sayeef Mirza, Lia Perez, Asmita Mishra, Farhad Khimani, Jose L. Ochoa-Bayona, Michael Nieder, Taiga Nishihori, Joseph A. Pidala, Nelli Bejanyan

Blood (2024) 144 (Supplement 1): 4881.

https://doi.org/10.1182/blood-2024-202709

Published: 2024

Journal Articles

De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression

Mark B. Meads, Xiaohong Zhao, David R. Noyes, Alexandra Achille, Praneeth Reddy Sudalagunta, Chaomei H. Zhang, Sonila Toska, Jongphil Kim, Samer Sansil, Sean J. Yoder, Ariel Grajales-Cruz, Brandon Blue, Ciara Louise Freeman, Melissa Alsina, Ariosto Siqueira Silva, Xiaofei Song, Rachid Baz, Kenneth H. Shain

Blood (2024) 144 (Supplement 1): 1906.

https://doi.org/10.1182/blood-2024-210232

Published: 2024

Journal Articles

Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation

Blood (2024) 144 (Supplement 1): 4826.

https://doi.org/10.1182/blood-2024-202363

Published: 2024

Journal Articles

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Jaime Roman Diaz, Saurabh Dahiya, Francesca Emily Sillito, Maeve O'Reilly, Kai Rejeski, Veit L. Buecklein, Marion Subklewe, Gloria Iacoboni, Pere Barba, Claire Roddie, Frederick Locke, Jay Y. Spiegel, Najla H. Al Ali, Zachary Thompson, Jongphil Kim, Rami S. Komrokji, Michael D. Jain

Blood (2024) 144 (Supplement 1): 7239.

https://doi.org/10.1182/blood-2024-201666

Published: 2024

Journal Articles

Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy

Jamila Mammadova, Yanina Pasikhova, Jongphil Kim, Junmin Whiting, Farhad Khimani, Michael D. Jain, Sayeef Mirza, Rawan Faramand, Julio C. Chavez, Bijal D Shah, Olga Klinkova, Aliyah Baluch, Jose L. Ochoa-Bayona, Fabiana Perna, Taiga Nishihori, Nelli Bejanyan, Frederick Locke, Aleksandr Lazaryan

Blood (2024) 144 (Supplement 1): 2103.

https://doi.org/10.1182/blood-2024-201878

Published: 2024

Journal Articles

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Blood (2024) 144 (Supplement 1): 2071.

https://doi.org/10.1182/blood-2024-208021

Published: 2024

Journal Articles

Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide

Blood (2024) 144 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2024-209164

Published: 2024

Journal Articles

A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes

Somedeb Ball, Najla H. Al Ali, Akriti G. Jain, Moazzam Shahzad, Junmin Whiting, Daniel Lastorino, Zhuoer Xie, Alison R. Walker, Onyee Chan, Eric Padron, Jongphil Kim, Jeffrey E Lancet, David Sallman, Sara M. Tinsley-Vance, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 532.

https://doi.org/10.1182/blood-2024-209273

Published: 2024

Journal Articles

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study

Blood (2024) 144 (Supplement 1): 1995.

https://doi.org/10.1182/blood-2024-206353

Published: 2024

Journal Articles

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 1048.

https://doi.org/10.1182/blood-2024-210830

Published: 2024

Journal Articles

Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia

Onyee Chan, Kendra L. Sweet, Chetasi Talati, Fatima Tuz Zahra, Lisa Ann Nardelli, Jatinder K. Lamba, Jongphil Kim, Jinming Song, Zhuoer Xie, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Rami S. Komrokji, Jeffrey E Lancet, David Sallman

Blood (2024) 144 (Supplement 1): 4270.

https://doi.org/10.1182/blood-2024-206161

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Refined elderly comorbidity index is highly predictive of post-transplant survival in older adults with Acute Myeloid Leukemia and myelodysplastic syndrome

Outcomes of elderly (≥ 70) Acute Myeloid Leukemia (AML) patients receiving continued hypomethylating agent/venetoclax (HMA/VEN) versus allogeneic hematopoietic cell transplantation (HCT)

Effect of GVHD prophylaxis on renal function and survival outcomes in allogeneic hematopoietic cell transplant patients with pre-existing renal impairment

Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML)

Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL)

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy

Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia

De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression

Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide

A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study

Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only